These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 17678651

  • 1. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
    Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J.
    Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
    [Abstract] [Full Text] [Related]

  • 2. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C.
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [Abstract] [Full Text] [Related]

  • 3. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial.
    Serna J, Cholquevilque JL, Cela V, Martínez-Salazar J, Requena A, Garcia-Velasco JA.
    Fertil Steril; 2008 Dec; 90(6):2190-5. PubMed ID: 18191847
    [Abstract] [Full Text] [Related]

  • 4. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
    Yıldız GA, Şükür YE, Ateş C, Aytaç R.
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
    [Abstract] [Full Text] [Related]

  • 5. A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders.
    DiLuigi AJ, Engmann L, Schmidt DW, Benadiva CA, Nulsen JC.
    Fertil Steril; 2011 Jun 30; 95(8):2531-3. PubMed ID: 21324455
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis.
    Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG.
    Fertil Steril; 2008 Dec 30; 90(6):2116-25. PubMed ID: 18178194
    [Abstract] [Full Text] [Related]

  • 8. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
    Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzis BC, Tournaye H, Devroey P.
    Fertil Steril; 2011 Nov 30; 96(5):1112-5. PubMed ID: 21924414
    [Abstract] [Full Text] [Related]

  • 9. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K, Berker B, Atabekoglu CS, Sonmezer M, Cetinkaya E, Aytac R, Satiroglu H.
    Fertil Steril; 2009 Jun 30; 91(6):2437-44. PubMed ID: 18555238
    [Abstract] [Full Text] [Related]

  • 10. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI, Chantilis SJ, Hurst BS, Dickey RP.
    Fertil Steril; 2005 Feb 30; 83(2):321-30. PubMed ID: 15705369
    [Abstract] [Full Text] [Related]

  • 11. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I, Mizrachi Y, Karfunkel-Doron D, Omer Y, Sheena L, Carmon N, Ben-David G.
    Fertil Steril; 2016 Aug 30; 106(2):330-3. PubMed ID: 27114332
    [Abstract] [Full Text] [Related]

  • 12. Effect of the initiation of progesterone supplementation in in vitro fertilization-embryo transfer outcomes: a prospective randomized controlled trial.
    Gao J, Gu F, Miao BY, Chen MH, Zhou CQ, Xu YW.
    Fertil Steril; 2018 Jan 30; 109(1):97-103. PubMed ID: 29175065
    [Abstract] [Full Text] [Related]

  • 13. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH, Wu FS, Lee RK, Li SH, Lin SY, Hwu YM.
    Fertil Steril; 2013 Nov 30; 100(5):1296-302. PubMed ID: 23993928
    [Abstract] [Full Text] [Related]

  • 14. Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase: A Randomized Controlled Trial.
    Maged AM, Nada AM, Abohamila F, Hashem AT, Mostafa WA, Elzayat AR.
    Reprod Sci; 2015 Dec 30; 22(12):1627-31. PubMed ID: 26045549
    [Abstract] [Full Text] [Related]

  • 15. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients.
    Tehraninejad ES, Nasiri R, Rashidi B, Haghollahi F, Ataie M.
    Arch Gynecol Obstet; 2010 Sep 30; 282(3):319-25. PubMed ID: 20379731
    [Abstract] [Full Text] [Related]

  • 16. A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.
    Scheffer JB, Scheffer BB, Carvalho RF, Aguiar AP, Lozano DHM, Labrosse J, Grynberg M.
    JBRA Assist Reprod; 2019 Aug 22; 23(3):239-245. PubMed ID: 30875186
    [Abstract] [Full Text] [Related]

  • 17. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB, Surrey ES, Minjarez DA, Stevens JM, Gardner DK.
    Fertil Steril; 2008 Jan 22; 89(1):151-6. PubMed ID: 17482177
    [Abstract] [Full Text] [Related]

  • 18. Luteal estrogen supplementation in stimulated cycles may improve the pregnancy rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer.
    Drakakis P, Loutradis D, Vomvolaki E, Stefanidis K, Kiapekou E, Anagnostou E, Anastasiadou K, Milingos S, Antsaklis A.
    Gynecol Endocrinol; 2007 Nov 22; 23(11):645-52. PubMed ID: 17999276
    [Abstract] [Full Text] [Related]

  • 19. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N, Chen Q, Hong Q, Cai R, Gao H, Wang Y, Sun L, Zhang S, Guo H, Fu Y, Ai A, Tian H, Lyu Q, Daya S, Kuang Y.
    Fertil Steril; 2016 Aug 22; 106(2):334-341.e1. PubMed ID: 27114329
    [Abstract] [Full Text] [Related]

  • 20. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A, Tsur A, Haas J, Yerushalmi GM, Hourvitz A, Machtinger R, Orvieto R.
    Fertil Steril; 2014 Jun 22; 101(6):1624-8. PubMed ID: 24680364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.